摘要
肾性高血压的患病率越来越高,但达标率很低,近年来各指南对肾性高血压的治疗目标意见不一。通过对比各指南的治疗目标及其变迁,可以看出,对于包括老年人及儿童在内的肾性高血压,其血压目标值仍颇具争议,但其总体趋势不单关注是否能够延缓肾损害,更加注重是否能够减少心血管事件发生,从而降低患者的病死率;通过分析各指南及建议,血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂(ACEI/ARB)类药物,钙通道阻滞剂类药物及利尿剂在治疗中应用最为广泛,其中ACEI/ARB类药物在治疗肾性高血压中占有重要地位。
The prevalence of renal hypertension is getting higher and higher, but the rate of compliance is very low.In recent years,various guidelines have different opinions on the treatment goals of renal hypertension.By comparing the treatment goals and their changes in each guideline,it can be seen that for renal hypertension in patients including the elderly and children,the target value is still controversial.But the overall trend is not just to focus on delaying kidney damage, but also on reducing cardiovascular events, thereby reducing mortality.By analyzing the guidelines and recommendations,it′s found that angiotensin coverting enzyme inhibitor（ACEI）/angiotensin Ⅱ receptor blocker（ARB） drugs,calcium channel blocker drugs and diuretics are the most widely used in the treatment, and ACEI/ARB drugs still play an important role in the treatment of renal hypertension.
作者
张秋平
李青
ZHANG Qiuping;LI Qing(Department of Nephrology,Tianjin TEDA Hospital,Tianjin 300457,China)
出处
《医学综述》
2018年第22期4385-4389,共5页
Medical Recapitulate
关键词
肾性高血压
血压目标值
药物治疗
Renal hypertension
Blood pressure goals
Medication
